Clinical Trials Directory

Trials / Completed

CompletedNCT02282579

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy, in Patients With Metastatic Renal Cell Carcinoma in Daily Clinical Practice

Status
Completed
Phase
Study type
Observational
Enrollment
300 (actual)
Sponsor
Spanish Oncology Genito-Urinary Group · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on efficacy and safety of pazopanib as a first-line therapy in practice usual for the clinical treatment of metastatic Renal Carcinoma.

Conditions

Interventions

TypeNameDescription
DRUGPazopanibNon interventional study

Timeline

Start date
2014-10-01
Primary completion
2015-02-01
Completion
2015-04-01
First posted
2014-11-04
Last updated
2018-04-26

Locations

34 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT02282579. Inclusion in this directory is not an endorsement.